Prospects and challenges in the introduction of human papillomavirus vaccines in the extended middle east and North Africa Region

Vaccine

Volumn 31, Issue S6, 2013, Pages

  Jumaan, Aisha O ^a   Ghanem, Soha ^b   Taher, Jalaa ^c   Braikat, Mhammed ^d   Awaidy, Salah Al ^e   Dbaibo, Ghassan S ^b  

^a American University of Beirut ^*

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c Ministry of Health United Arab Emirates   (United Arab Emirates)

^d Ministry of Health Morocco   (Morocco)

^e MINISTRY OF HEALTH   (Oman)

Author keywords

Adolescent; Cervical cancer; Extended Middle East and North Africa; HPV; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE;

AFGHANISTAN; ALGERIA; BAHRAIN; DRUG COST; DRUG SAFETY; EGYPT; HUMAN; INCOME; IRAN; IRAQ; JORDAN; KUWAIT; LEBANON; LIBYAN ARAB JAMAHIRIYA; MEDICAL DECISION MAKING; MIDDLE EAST; MOROCCO; NORTH AFRICA; OMAN; PAKISTAN; PAPILLOMAVIRUS INFECTION; PERCEPTION; POLITICS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QATAR; REVIEW; SAUDI ARABIA; SYRIAN ARAB REPUBLIC; TUNISIA; TURKEY (REPUBLIC); UNITED ARAB EMIRATES; VACCINATION; YEMEN;

ADOLESCENT; CERVICAL CANCER; EXTENDED MIDDLE EAST AND NORTH AFRICA; HPV; VACCINATION;

ADOLESCENT; AFRICA, NORTHERN; FEMALE; HEALTH POLICY; HEALTH SERVICES ADMINISTRATION; HUMANS; MIDDLE EAST; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 84890062404     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.097     Document Type: Review

References (40)

1. http://www.technet21.org/index.php/documents/view-document-details/1286-global-hpv-vaccine-licensure-status-june-2011.html.Map_Global_HPV_vaccine_licensure_status_2011Jun.pdf (last accessed March 2012).
2. Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet 2007 Jun 2; 369(9576):1861-8.
3. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009 Jul 25, 374(9686):301-314.
4. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008 Aug 19;26 Suppl 10:K53-61.
5. World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009 Apr 10;84(15):118-31.
6. Lim S.S., Stein D.B., Charrow A., Murray C.J. Tracking progress towards universal childhood immunization and the impact of global initiatives: a systematic analysis of three-dose diphtheria, tetanus, and pertussis immunization coverage. Lancet 2008 Dec 13, 372(9655):2031-2046.
7. Centers for Disease Control and Prevention (CDC). Global routine vaccination coverage, 2009. MMWR 2010 Oct 29; 59(42):1367-71.
8. World Health Assembly resolution 58.15, Geneva, Switzerland, May 16-25, 2005.
9. (last accessed March 2012). http://www.childinfo.org/files/immunization_summary_en.pdf.
10. (last accessed March 2012). http://www.who.int/immunization/GIN_February_2012.pdf.
11. http://www.rostropovich.org/en/west-bank-and-gaza (last accessed June 2013).
12. http://www.unrwa.org/userfiles/2010011610371.pdf (last accessed on June 2013).
13. WHO Regional Committee for the Eastern Mediterranean, Fifty-eighth session EMRO, EM/RC58/4: Scaling up the Expanded Programme on Immunization to meet global and regional targets, Cairo, 2-5 October 2011.
14. Clements CJ, Chandra-Mouli V, Byass P, Ferguson BJ. Global strategies, policies and practices for immunization of adolescents. WHO 1999/V&B/99.24.
15. WHO Regional Consultation to Standardize EPI schedule in the Eastern Mediterranean Region of the World Health Organization. Consultation on EPI schedule, EMRO, Oct 2006, VPI/EMRO, Mar 2008.
16. http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tscoveragett2plus.htm (last accessed May 2012).
17. Vaccination coverage among adolescents aged 13-17 years-United States, 2007. MMWR 2008; 57:1100-3.
18. Brabin L., Roberts S.A., Stretch R., Baxter D., Chambers G., Kitchener H., et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: Prospective cohort study. BMJ 2008, 336:1056-1058.
19. LaMontagne D.S., Barge S., Le N.T., Mugisha E., Penny M.E., Gandhi S., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011 Nov 1, 89(11). 821-30B.
20. Luciani S., Jaurequi B., Kieny C., Andrus J.K. Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries. Immunotherapy 2009 Sep, 1(5):795-807.
21. Brabin L., Greenberg D.P., Hessel L., Hyer L., Ivanoff B., Van Damme P. Current issues in adolescent immunization. Vaccine 2008 Aug 5, 26(33):4120-4134.
22. Castellsagué X., Claeys P., Cutts F.T., Goldie S., Franceschi S., de Sanjose S., et al. Human papillomavirus and HPV vaccines: Technical information for policy-makers and health professionals. Bull World Health Organ 2007 Sep, 85(9):719-726.
23. Broutet N., Huntington D., Cutts F., Hall P. Preparing for the introduction of HPV vaccines: policy and programme guidance for countries. WHO 2006.
24. (last accessed May 2012). http://www.unicef.org/progressforchildren/2007n6/index_41798.htm.
25. Anonymous Middle East NCD Strategy. Lancet 2012;379 (9812):i.
26. Bhattacharjee M. MoH to introduce hepatitis A, rotavirus and HPV vaccines. Muscat Daily Sep 20th, 2011.
27. Jacob M., Mawar N., Menezes L., Kaipilyawar S., Gandhi S., Khan I., et al. Assessing the environment for introduction of human papillomavirus vaccine in India. Open Vaccine J 2010, 3:96-107.
28. Bartolini R.M., Kidwell Drake J., Creed-Kanashiro H.M., Díaz-Otoya M.M., Mosqueira N.R. Formative research to shape HPV vaccine introduction strategies in Peru. Salud Pública de México. 2010, 52(3):226-233.
29. Katahoire R.A., Jitta J., Kivumbi G., Murokora D., Arube Wani J., Siu G., et al. An assessment of the readiness for introduction of the HPV vaccine in Uganda. Afr J Reprod Health 2008, 12(3):159-172.
30. Knowledge Sait K.H. attitudes, and practices regarding cervical cancer screening among physicians in the Western Region of Saudi Arabia. Saudi Med J 2011, 32(11):1155-1160.
31. Ali S.F., Ayub S., Manzoor N.F., Azim S., Afif M., Akhtar N., et al. Knowledge and awareness about cervical cancer and its prevention amongst interns and nursing staff in tertiary care hospitals in Karachi, Pakistan. PLoS One 2010, 5(6):e11059.
32. Al Nuaimi N.S., Al Ghas Y.S., Al Owais A.H., Grivna M., Scheinder J., Nagelkerke N.J., et al. Human papillomavirus vaccination uptake and factors related to uptake in a traditional desert city in the United Arab Emirates. Int J STD and AIDS 2011, 22:400-404.
33. Durusoy R., Yamazhan M., Tasbakan M.I., Ergin I., Aysin M., Pullukcu H., et al. HPV vaccine awareness and willingness of first-year student entering university in Western Turkey. Asia Pac J Cancer Prev 2010, 11(6):1695-1701.
34. Dursun P., Altuntas B., Kuscu E., Ayhan A. Women's knowledge about human papillomavirus and their acceptance of HPV vaccine. Aust N Z J Obstet Gynaecol 2009, 49:202-206.
35. Marlow L.A.V., Waller J., Evans R.E.C., Wardle J. Predictors of interest in HPV vaccination: A study of British adolescents. Vaccine 2009, 27:2483-2488.
36. Marlow L.A.V., Wardle J., Forster A.S., Waller J. Ethnic differences in human papillomavirus awareness and vaccine acceptability. J Epidemiol Community Health 2009, 63:1010-1015.
37. Rouzier R., Giordanella J.P. Coverage and compliance of Human Papillomavirus vaccines in Paris: demonstration of low compliance with non school based approaches. J Adolesc Health September 2010, 47(3):237-241.
38. Kim J.J., Sharma M., O'Shea M., Sweet S., Diaz M., Sancho-Garnier H., et al. Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in the Extended Middle East and North Africa (EMENA). Vaccine 2013, 31S:G65-G77.
39. Shaping a strategy to introduce HPV vaccines in India: Formative research results from the HPV vaccines: Evidence for impact project (2009). Available at: http://www.rho.org/HPV-vaccine-implementation.htm (last accessed June 2013).
40. Kaufmann A.M., Schneider A. New paradigm for prevention of cervical cancer. Eur J Obstet Gynec Reproduct Biol 2007, 130(1):25-29.